- LOGIN
- MemberShip
- 2020-09-26 22:20
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Policy
- More than 20 companies, to apply for Atozet's generics
- by Lee, Tak-Sun Sep 25, 2020 06:05am
- It is reported that more than 20 pharmaceutical companies have contracted to produce generics for Atozet (Ezetimibe/Atorvastatin) with Chong Kun Dang. Accordingly, it is expected that the number of drugs applied for permission after PMS through bioequivalence test will be lowered by about 15% compared to Chong Kun Dang products. Chong K
- Policy
- The post-assessment system has many problems
- by Lee, Hye-Kyung Sep 25, 2020 06:05am
- The necessity of introducing post-assessment system for prior registration was raised to expand patient access to new drugs, but the government said it needed complex concerns. Choi Gyeong-ho, an official at the insurance pharmaceutical department of the MOHW, said at the 'Non-face-to-face discussion for enhancing patient accessibility of
- Policy
- Better new drug access with pre-listing reimbursement
- by Lee, Hye-Kyung Sep 25, 2020 06:04am
- Pharmaceutical affairs expert argues, to enhance patients’ access to new drugs, the government should induce pharmaceutical companies to voluntarily set and lower generic pricing on their own, while also considering flexible ICER threshold and pre-listing reimbursement. And the expert criticizes the upcoming pilot program, effective from Oc
- Policy
- The generic competition of Circadin PR is intensifying
- by Lee, Tak-Sun Sep 25, 2020 06:04am
- Generics for Circadin PR, a melatonin-based insomnia treatment drug, began to be approved on the 22nd. Kuhnil's Circadin PR was removed from data protection due to the expiration of PMS in June. With the end of PMS, applications for permission for generic drugs were followed, and product approval was finally received this month. Prior to the
- Policy
- The answer is to improve the drug price system
- by Lee, Hye-Kyung Sep 24, 2020 06:20am
- The drug price system should be improved in order to enhance patient access to new drugs such as cancer and rare disease treatments. Through the 'non-face-to-face discussion to enhance patient accessibility of new drugs in the era of COVID-19' hosted by Lee Yong-ho, a member of the National Assembly and hosted by the Future Health Network on
- Policy
- Certican keeps weighted pricing for now, Samsca lowered 30%
- by Kim, Jung-Ju Sep 24, 2020 06:19am
- Novartis Korea’s immunosuppressant Certican (everolimus) has ultimately dodged the double pricing reduction. Although dismissed from patent litigation and lost from the administrative litigation against the government, the immunosuppressant is to keep its premium pricing benefit as stipulated by the policy that sustains the benefit when the num
- Policy
- Italian-made Gliatirin and Vesseldue-F efficacy questioned
- by Lee, Tak-Sun Sep 23, 2020 06:21am
- A series of drugs from Italian manufacturers are in a tight spot, as they have been selected as an efficacy reevaluation subjects. These drugs do not have sufficient evidence to prove the efficacy, because they hardly have much records of use in countries other than South Korea. The pharmaceutical industry sources reported on Sept. 20, S
- Policy
- Generic companies for Atozet are interested in contractors
- by Lee, Tak-Sun Sep 22, 2020 06:27am
- It is known that generic companies of the hyperlipidemia complex Atozet(Atorvastatin-Ezetimibe, Chong Kun Dang) will sign a consignment contract with Chong Kun Dang today (22nd). Generic companies are paying attention to the number of final contractors and scrutinizing their strengths and weaknesses. According to the industry on the 21st
- Policy
- ORR 100%, Phase III of Lazertinib combination was approved
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- The clinical trial of Lazertinib-Amivantamab, which was released by Janssen at the European Society for Medical Oncology (ESMO) on the 20th, is also being conducted in Korea. As a result of this interim study, the response rate (ORR) was 100%, raising expectations as a treatment for non-small cell lung cancer that threatens Tagrisso. Laz
- Policy
- Goal of generic for Atozet is to be approved in next January
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- Chong Kun Dang's consignment-produced hyperlipidemia combination drug 'Atozet (Atorvastatin-Ezetimibe) is known to have applied for approval this month and is aiming for approval in next January. In that Atozet’s PMS by MDS will expire in next January, it is faster to acquire product approval than generics that have undergone bioequivalen
